Abbreviations & Acronyms AA = African American CI = confidence interval CSM = cancer-specific mortality EAPC = estimated annual percentage changes GGG = Gleason grade group IQR = interquartile range LND = lymph node dissection LNI = lymph node invasion NHW = non-Hispanic white NIH = National Institutes of Health OR = odds ratio PCa = prostate cancer PSA = prostate-specific antigen RP = radical prostatectomy SEER = Surveillance, Epidemiology and End Results Objectives: To test for racial disparities in lymph node dissection rates, lymph node dissection extent, lymph node invasion rates and cancer-specific mortality in North American African Americans versus non-Hispanic whites, at radical prostatectomy for clinically localized prostate cancer. Methods: Within the Surveillance, Epidemiology and End Results database (2010-2014), we identified 58 974 African Americans or non-Hispanic whites with prostate cancer, who underwent radical prostatectomy with available clinical stage, prostate-specific antigen and biopsy Gleason score. Annual trends were examined. Logistic regression models focused on lymph node dissection rates, lymph node dissection extent (number of removed lymph nodes) and lymph node invasion. Cox regression models tested for differences in cancerspecific mortality. Multivariable models were adjusted for D'Amico risk groups, age and year. Models predicting lymph node invasion and cancer-specific mortality were additionally adjusted for lymph node dissection extent. Results: Among all patients, 14.5% were African Americans. Lymph node dissection was carried out in 60.0% of African Americans versus 59.5% of non-Hispanic whites (P = 0.4). The median number of removed lymph nodes was five in African Americans versus six in non-Hispanic whites (P < 0.001). Furthermore, 3.1% versus 3.3% of African Americans and non-Hispanic whites, respectively, harbored lymph node invasion (P = 0.3). In multivariable logistic regression models African American race did not affect lymph node dissection or lymph node invasion rates, but lymph node dissection extent was lower in African Americans (hazard ratio 0.9; P < 0.001). No statistical differences in cancer-specific mortality were identified according to race. Conclusions: Contemporary North American African American patients treated with radical prostatectomy have equal access to lymph node dissection, the same lymph node invasion rates and the same cancer-specific mortality rates as non-Hispanic whites. However, the extent of lymph node dissection is lower in African Americans. The results regarding lymph node dissection rates are encouraging. However, improvements are required regarding lymph node dissection extent in African Americans.
Introduction
Several investigators showed racial disparities in the quality of care for localized PCa. [1] [2] [3] [4] [5] [6] Specifically, racial disparities and barriers to care among AA patients applied to the use of definitive therapy for localized PCa. 1, [3] [4] [5] This phenomenon affected the rates of RP, which were lower in AAs than in NHWs. 6 A similar phenomenon was recorded for rates of LND at RP. Within the SEER database, Hayn et al. reported that AA men less frequently undergo LND. 5 Within the SEER-Medicare linked database, Schmid et al. also reported lower LND rates in AAs. 1 However, both studies relied on historical cohorts. Hayn et al. studied men treated between 2000 and 2002. Schmid et al. relied on an even more historic cohort that spanned the years 1991-2009. Since then, significant efforts were made to eliminate racial disparities pertaining to diagnosis, as well as to treatment of localized PCa. As a consequence, we hypothesized that such disparities have been eliminated regarding LND. To test our hypothesis, we relied on the SEER database (2010-2014) and examined not only LND rates, but also the extent, defined as the number of removed lymph nodes, as well as LNI rates and CSM rates according to AA versus NHW.
Methods

Study population
Within the SEER database (2010-2014), we identified 58 974 patients ( Fig. 1 ) with complete information on clinical tumor stage, PSA values and biopsy GGG, aged 30-79 years and treated with RP. 7 No patient had a PSA >50 ng/mL (i.e. suspected metastatic disease) 8 or confirmed metastatic disease at diagnosis. CSM was defined as death attributable to PCa diagnosis, according to the SEER cause-of-classification. D'Amico risk groups were defined as: low-risk (clinical stage T1c-T2a, PSA <10.0 ng/mL and GGG1), intermediate-risk (clinical stage T2b and/or PSA 10-20 ng/mL, and/or GGG2 or GGG3) and highrisk (clinical stage ≥T2c, PSA >20 ng/mL and/or GGG ≥4).
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Statistical analysis
Descriptive statistics included frequencies and proportions for categorical variables. Medians and IQRs were reported for continuously coded variables. The v 2 tested the statistical significance in proportions' differences. The Mann-Whitney U-test examined the statistical significance of medians' differences.
The EAPC, based on logistic regression models, were used for annual trend analyses. Furthermore, three separate multivariable logistic regression models focused on the three separate outcomes: LND rates, LND extent (above median) and LNI rates. In all multivariable logistic models, adjustment was made for D'Amico risk groups, year of surgery and age. The model predicting LNI was additionally adjusted for the number of removed lymph nodes. Finally, two separate multivariable Cox regression models focused on CSM rates according to race. In the first model that focused on CSM rates, adjustment was made for D'Amico risk groups, number of removed lymph nodes, presence or absence of LNI, year of surgery and age. In the second model that focused on CSM rates, adjustment was made for pathological tumor stage, RP Gleason, PSA, number of removed lymph nodes, presence or absence of LNI, year of surgery and age. R software environment for statistical computing and graphics (version 3.4.0; R Foundation for Statistical Computing, Vienna, Austria) was used for all statistical analyses. All tests were two-sided, with a level of significance set at P < 0.05.
Results
Descriptive characteristics
Of 58 974 (Table 1) 
Effect of AA race on LND rates
Overall, LND was carried out in 60.0% of AA versus 59.5% of NHW patients (P = 0.4). The annual LND rates (Fig. 2a) increased during the study period from 56.9% to 66.8% in AAs (EAPC: 5.23%, P = 0.008) versus 55.9% to 66.0% in NHWs (EAPC: 4.25%, P = 0.02), respectively.
Initial assessment of annual trends according to the D'Amico risk groups (Fig. 2b,c) showed virtually the same results in AAs and NHWs. However, when annual trends were more closely examined, racial disparities emerged. Specifically, annual trends in AAs only showed an increase in the rate of LND (Fig. 2b) in the D'Amico intermediaterisk group (EAPC: 4.95%, P = 0.03). Conversely, in NHW men (Fig. 2c) , annual trends only showed an increase in the rate of LND in the D'Amico high-risk group (EAPC: 2.3%, P = 0.007). In all other D'Amico risk groups, no statistical significant changes either in AAs or NHWs occurred. Multivariable logistic regression models (Table 2) showed that AA race did not result in LND rate differences between AA versus NHW men (OR 0.98, 95% CI 0.9-1.0, P = 0.5).
Effect of AA race on LND extent
In patients who underwent LND (n = 35 144), the median number of removed lymph nodes was five (IQR 3-10) in AAs versus six (IQR 3-11) in NHWs (P < 0.001), respectively. Furthermore, in both races, the median number of removed lymph nodes (Fig. 3) increased in a non-significant fashion (5-6, P = 0.06) during the study period (2010-2014). Multivariable logistic regression models predicting LND extent (above the median; Table 2) showed that AA race is a predictor of less extensive LND relative to NHWs (OR 0.9, 95% CI 0.8-0.9, P < 0.0001).
Effect of AA race on LNI rates
Of all RP patients who underwent a LND (n = 35 144), 5.2% of AAs versus 5.6% of NHWs harbored LNI (P = 0.2). The annual rates of LNI (Fig. 4a ) did not change in AA men (EAPC: 0.04%, P = 0.99). Conversely, in NHWs, a significant increase in the LNI rates was recorded (EAPC: 13.04%, P = 0.001). Here, the LNI rates increased from 4.5% to 7.1% during the study period. However, after further adjustment for LND extent (Fig. 4b) , virtually the same LNI rates were recorded in AA and NHW men. Multivariable logistic regression models predicting LNI ( Table 2 ) also showed that AA race did not result in LNI rate differences relative to NHW men (OR 0.97, 95% CI 0.8-1.1, P = 0.7).
Effect of AA race on CSM
Of all RP patients who underwent LND (n = 35 144), the mean follow-up period was 30.7 months. CSM at 48 months after RP was 0.6% versus 0.5% for AAs versus NHWs, respectively, without LNI. Conversely, it was 1.1% versus 2.8% in AAs versus NHWs, respectively, with LNI. In multivariable Cox regression models (Table S1 ) predicting CSM, after adjustment for clinical tumor characteristics, AA race was not an independent predictor (hazard ratio 1.3, 95% CI 0.8-2.0, P = 0.3). Similarly, AA race was not an independent predictor of CSM after adjustment for pathological tumor characteristics (hazard ratio 1.4, 95% CI 0.9-2.3, P = 0.1). • RP not performed
• non-African American or non-Hispanic white
• missing Gleason grade group
• missing clinical tumor stage 
Discussion
Previous studies reported disparities between AA and NHW men regarding the use of definitive therapy for localized PCa. 1, [3] [4] [5] Specifically, two previous studies reported that AA men are less frequently treated with LND at RP. 1, 5 However, both studies relied on historical cohorts and since then, it is plausible that barriers to care affecting AAs have disappeared. Our objective was therefore, to examine contemporary racial differences in men treated with RP for localized PCa. Specifically, we tested the relationship between AA race and LND rates, LND extent, LNI rates and CSM using a large contemporary North American patient cohort. Our analyses revealed several noteworthy findings.
First, no significant differences in LND rates were recorded between AA and NHW patients (60.0% vs 59.5%, P = 0.4). Furthermore, in multivariable logistic regression models, AA race did not predict LND (OR 0.98, P = 0.5). These observations differ from previous reports. Schmid et al. (1991 Schmid et al. ( -2009 and Hayn et al. (2000 Hayn et al. ( -2002 reported that AA men less frequently undergo LND. 1, 5 However, both historic reports relied on smaller sample sizes and lower proportions of AA patients. The proportion of AA men in the analyses by Schmid et al. was 7.6% (n = 2020) and 11% (n = 4489) in the analyses by Hayn et al., compared with 14.5% (n = 8543) in the current study. Taken together, the present findings show that efforts have been made to eradicate racial disparities between AAs and NHWs regarding access to LND at RP. This finding is highly encouraging. Specifically, within the past decade, a PubMed search combining the terms "racial disparities" and "PCa," revealed 306 publications, addressing this topic. This finding is indicative of the importance being given to racial disparities in PCa. This very phenomenon represents an effort to alert and sensitize the urological community to the presence of racial disparities that are invariably interpreted as an unwanted phenomenon, and invariably encourage the urological community to reduce or eliminate differences in rates according to race. Furthermore, specific efforts have been made to encourage research and to directly decrease residual racial disparities. An example is the Healthy People 2010 Initiative in which the NIH mandated that all biomedical and behavioral research funded by the NIH must include plans to recruit and retain minorities as participants. Furthermore, the NIH created the National Center for Minority Health and Health Disparities, with the express purpose of promoting and supporting research aimed at eliminating health disparities in racial and ethnic minorities. 10 Second, we also found that the extent of LND differs between AA and NHW men. The median number of removed lymph nodes was five in AA versus six in NHW patients (P < 0.001), respectively. Furthermore, in multivariable logistic regression models, AA race was an independent predictor of LND extent (OR 0.9, P < 0.0001). Taken together, these findings show that despite equal access to LND, its extent differs according to race, where AAs benefit from less extensive LND. To the best of our knowledge, no previous group of investigators analyzed LND extent according to race. Furthermore, an explanation of this phenomenon can only be based on hypotheses. Among those, physician-driven choice might represent one of the explanations towards a more limited LND in AAs. It is also possible that on average, lower lymph node counts are present within the distribution of LND in AAs. Furthermore, it could also be hypothesized that lymph node identification at the time of pathological specimen assessment is carried out less succinctly in AA than it is in NHW patients, and as a consequence fewer lymph nodes are identified. However, none of these hypotheses has ever been formally tested and in consequence, they are speculative at best. Ideally, LND extent should be quantified with detailed LND mapping. However, such detailed information is rarely, if ever, available, even in tertiary care databases. For example, Briganti et al. relied on high-quality institutional databases to introduce and eventually validate the concept of LND extent without having access to detailed mapping information. 11 In all their analyses, lymph node counts represented proxies for LND extent. In the current study, we relied on the same concept, where lymph node count represents a proxy of LND extent. The lymph node count differences might appear trivial. However, they do illustrate a difference in the LND extent between AA and NHW. The latter is based on one lymph node difference, which is statistically significant and we believe clinically meaningful. This said, the observed difference is not intended to guide clinicians and recommend dissection of one additional node in AA patients to obliterate the discrepancy between AA and NHW patients. Instead, the present findings are intended to illustrate a general tendency, where more extensive LNDs are carried out in NHWs relative to AAs. This observation shows residual racial disparities. In consequence, further efforts are required to eradicate such differences. Third, we found no differences between AAs and NHWs in LNI rates. This finding might corroborate similarity in tumor biology between the two races, and also previous reports where AA race was not an independent predictor for LNI. 12, 13 Even though no clinical meaningful differences exist with respect to clinical tumor stage, residual differences remain with respect to PSA and D'Amico risk groups. As a consequence, we cannot fully refute the contemporary applicability of historical reports, where higher tumor stage and higher Gleason grade at presentation were reported in AA patients. [14] [15] [16] [17] [18] However, the degree to which AAs harbor more aggressive PCa phenotypes at presentation appears to have lessened. As the present results originate only from a single database, they might not be generalizable, and further studies are required to confirm our findings.
Finally, we found no differences in CSM rates between AAs and NHWs after adjustment for either clinical or pathological tumor characteristics. This observation might also show similarity in tumor biology between the two races when adjustment is made either for clinical or pathological tumor characteristics. However, AAs are much more likely to be diagnosed at an advanced stage of PCa, which also drives CSM. 1, 17, 18 Furthermore, because of the short follow-up period, the present results are only preliminary and apply only to the database at hand.
The present study was not devoid of limitations. Only a proportion of individuals who were candidates for active treatment represent surgical candidates, and a proportion of these individuals opt for surgery. In consequence, a large number of patients with clinically localized PCa are treated with other treatment modalities than RP with LND. In the current study, we focused on all patients treated with RP and LND. Nevertheless, we acknowledge that LND was not essential and not a guideline recommended in a proportion of patients, namely in patients with D'Amico low-risk characteristics. Additionally, LND only provides improved staging information and its benefit in terms of cancer control outcomes is still under debate. Nevertheless, the National Comprehensive Cancer Network and European Association of Urology guidelines for PCa do recommend a LND in intermediate-and high-risk patients. 19, 20 Furthermore, the SEER database provides lymph node counts without defining specific anatomical LND templates, and the extent of LND varies from patient to patient. All of these limitations affect both races equally, except for LND extent, as we have shown in the current study. Additionally, LND and its extent represents only one of multiple quality of care indicators for patients treated with RP. Unfortunately, the SEER database does not contain other quality of care indicators of RP, which ideally should be observed in regard of racial disparities, such as perioperative complications, treatment delay, re-operations, costs and readmission rates. Furthermore, central pathology is not available in the SEER database, without differentially affecting either of the races. The SEER database also does not contain information regarding neoadjuvant hormonal therapy. 21 However, use of neoadjuvant hormonal therapy had been abandoned before the start day of the study. The present study also shares limitations of all similar studies that were based on the SEER database and relied on a retrospective data design. 21 Furthermore, despite the large sample size, the current study cohort only represents approximately 30% of the population sample with inherent limitations. 22 Despite having the largest absolute and relative numbers of AAs compared with all previous studies that focused on racial disparities in LND rates, AAs do represent a minority relative to NHWs in the current study (14.5%). 1, 5 This proportion is reflective of the distribution of AA men in the USA population. 23 Unfortunately, the SEER database does not allow to adjust for tumor immunobiological differences, which have been shown to be different in AAs and NHWs. 24 Finally, the SEER database also does not cover adjuvant treatment information, such as androgen deprivation or adjuvant radiotherapy. Racial disparities in adjuvant treatment options could have influenced our results in regard of CSM. Therefore, future studies are required to observe racial disparities in adjuvant treatment modalities.
In conclusion, contemporary North American AA patients treated with RP have equal access to LND, same LNI rates and CSM rates as NHWs. However, the extent of LND is lower in AAs than NHWs. The results regarding LND rates are encouraging. However, improvements are required regarding LND extent in AAs.
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